{"title":"慢性丙型肝炎的现有和新兴研究药物:现状","authors":"R. Kumar","doi":"10.5580/1a5e","DOIUrl":null,"url":null,"abstract":"Chronic hepatitis C is caused by flavi virus (RNA virus) and is the leading cause for cirrhosis, hepatocellular carcinoma and liver transplantation. The standard therapy of chronic hepatitis C is peg interferon α weekly plus oral-ribavirin daily is not effective in all patients and is limited by adverse effect. Therefore new investigational drugs are being developed and in pipeline. This article focuses on new investigational drugs that are presently in an advance stage of development also focuses on newer interferons, ribavirin analogue and anti apoptotic drug.","PeriodicalId":22523,"journal":{"name":"The Internet Journal of Pharmacology","volume":"37 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Present And Emerging Investigational Drugs For Chronic Hepatitis C: Current Status\",\"authors\":\"R. Kumar\",\"doi\":\"10.5580/1a5e\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic hepatitis C is caused by flavi virus (RNA virus) and is the leading cause for cirrhosis, hepatocellular carcinoma and liver transplantation. The standard therapy of chronic hepatitis C is peg interferon α weekly plus oral-ribavirin daily is not effective in all patients and is limited by adverse effect. Therefore new investigational drugs are being developed and in pipeline. This article focuses on new investigational drugs that are presently in an advance stage of development also focuses on newer interferons, ribavirin analogue and anti apoptotic drug.\",\"PeriodicalId\":22523,\"journal\":{\"name\":\"The Internet Journal of Pharmacology\",\"volume\":\"37 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Internet Journal of Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5580/1a5e\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Internet Journal of Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5580/1a5e","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Present And Emerging Investigational Drugs For Chronic Hepatitis C: Current Status
Chronic hepatitis C is caused by flavi virus (RNA virus) and is the leading cause for cirrhosis, hepatocellular carcinoma and liver transplantation. The standard therapy of chronic hepatitis C is peg interferon α weekly plus oral-ribavirin daily is not effective in all patients and is limited by adverse effect. Therefore new investigational drugs are being developed and in pipeline. This article focuses on new investigational drugs that are presently in an advance stage of development also focuses on newer interferons, ribavirin analogue and anti apoptotic drug.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
